The Lancet Respiratory Medicine
订阅
1. [Spotlight] Lifetime non-smoker survives stage IV lung cancer four times Tony Kirby
2. [Comment] 5 years of COVID-19: equity must lead the next pandemic response in a fractured multipolar world David S C Hui, Dorothy Yeboah-Manu, Jean B Nachega, Alfonso J Rodriguez-Morales, Tieble Traore, Markus Maeurer, Guiseppe Ippolito, Adam Zumla, Rizwan Ahmed, Osman Dar, Adeeba Kamarulzaman, Alimuddin Zumla
3. [Articles] Development of an asthma health-care burden score as a measure of severity and predictor of remission in SARP III and U-BIOPRED: results from two major longitudinal asthma cohorts Joe G Zein, Nazanin Zounemat-Kerman, Ian M Adcock, Bo Hu, Amy Attaway, Mario Castro, Sven-Erik Dahlén, Loren C Denlinger, Serpil C Erzurum, John V Fahy, Benjamin Gaston, Annette T Hastie, Elliot Israel, Nizar N Jarjour, Bruce D Levy, David T Mauger, Wendy Moore, Michael C Peters, Kaharu Sumino, Elizabeth Townsend, Prescott Woodruff, Victor E Ortega, Sally E Wenzel, Deborah A Meyers, Kian Fan Chung, Eugene R Bleecker, Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) Consortium and the the US National Heart, Lung, and Blood Institute Severe Asthma Research Program (SARP III)
4. [Comment] A composite burden score for severe asthma Jean Bousquet, Renaud Louis, Bernardo Sousa-Pinto
5. [Corrections] Correction to Lancet Respir Med 2024; published online Oct 29. https://doi.org/10.1016/S2213-2600(24)00264-9
6. [Articles] Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial Dongsheng Yue, Wenxiang Wang, Hongxu Liu, Qixun Chen, Chun Chen, Lunxu Liu, Peng Zhang, Guofang Zhao, Fan Yang, Guang Han, Ying Cheng, Bentong Yu, Yue Yang, Haiquan Chen, Jie Jiang, Lijie Tan, Shidong Xu, Naiquan Mao, Jian Hu, Lanjun Zhang, Bin Yao, Shengfei Wang, Rui-Hua Wang, Wenjuan Zheng, Changli Wang, RATIONALE-315 investigators
7. [Comment] New territories: perioperative chemoimmunotherapy in early-stage NSCLC Yusuke Okuma
8. [Editorial] One health, one flu: the re-emergence of avian influenza The Lancet Respiratory Medicine
9. [News] Health care in Ukraine: If everybody leaves, who will stay? Talha Burki
10. [Comment] Asthma remission: a call for a globally standardised definition Marek Lommatzsch, J Christian Virchow
11. [Articles] Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis Amy Shackleford, Liam G Heaney, Charlene Redmond, P Jane McDowell, John Busby
12. [Spotlight] Thoracentesis: an old story and some new sources Emmanuel Drouin, Eric Wiel, Edouard Lansiaux, Jacalyn Duffin, Arnaud Chambellan
13. [Comment] Managing tuberculosis before the onset of symptoms Dennis Falzon, Cecily Miller, Irwin Law, Katherine Floyd, Nimalan Arinaminpathy, Matteo Zignol, Tereza Kasaeva
14. [Correspondence] Health promotion in the management of respiratory diseases: an Indian perspective Arundhati Garud, Debabani Biswas, Saibal Moitra, Subhabrata Moitra
15. [Articles] Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08–2015 ENERGY): a randomised, open-label, phase 3 study Hervé Léna, Laurent Greillier, Claire Cropet, Olivier Bylicki, Isabelle Monnet, Clarisse Audigier-Valette, Lionel Falchero, Alain Vergnenègre, Pierre Demontrond, Margaux Geier, Florian Guisier, Stéphane Hominal, Chrystèle Locher, Romain Corre, Christos Chouaid, Charles Ricordel, GFPC 08–2015 ENERGY investigators
16. [Comment] First-line treatment for advanced NSCLC in older patients and those with poor performance status Ziming Li, Shun Lu
17. [Articles] Nintedanib for patients with lymphangioleiomyomatosis: a phase 2, open-label, single-arm study Sergio Harari, Davide Elia, Antonella Caminati, Jens Geginat, Francesca Luisi, Giuseppe Pelosi, Claudia Specchia, Olga Torre, Roberta Trevisan, Chiara Vasco, Maurizio Zompatori, Roberto Cassandro
18. [Comment] The challenge of therapeutic options for patients with lymphangioleiomyomatosis Maria Molina-Molina
19. [News] Youth vaping rates drop in US, but experts remain concerned Bryant Furlow
20. [News] UK COVID-19 booster vaccination programme Priya Venkatesan
21. [Corrections] Correction to Lancet Respir Med 2024; 12: 799–809
22. [Articles] Global, regional, and national burden of pulmonary arterial hypertension, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 GBD 2021 Pulmonary Arterial Hypertension Collaborators
23. [Comment] The global burden of pulmonary arterial hypertension: profound but improving? Joseph Newman, Joanna Pepke-Zaba
24. [News] Mixed news on air pollution and child lung health Udani Samarasekera
25. [Viewpoint] Empirical antibiotic therapy for sepsis: save the anaerobic microbiota Robert F J Kullberg, Bastiaan W Haak, Rishi Chanderraj, Hallie C Prescott, Robert P Dickson, W Joost Wiersinga
26. [Spotlight] Survival of sepsis masked by medications that hid diverticulitis Tony Kirby
27. [Articles] Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial Ruth L Goodall, Andrew J Nunn, Sarah K Meredith, Adamu Bayissa, Anuj K Bhatnagar, Chen-Yuan Chiang, Francesca Conradie, Narendran Gopalan, Meera Gurumurthy, Bruce Kirenga, Nana Kiria, Daniel Meressa, Ronelle Moodliar, Nosipho Ngubane, Mohammed Rassool, Karen Sanders, Rajesh Solanki, S Bertel Squire, Mekonnen Teferi, Gabriela Torrea, Bazarragchaa Tsogt, Elena Tudor, Armand Van Deun, I D Rusen, STREAM study collaborators
28. [Comment] Towards shorter, safer, flexible, and more effective treatment regimens for drug-resistant tuberculosis Keertan Dheda, Christoph Lange
29. [Articles] Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial Ze-Rui Zhao, Shi-Liang Liu, Ting Zhou, Gang Chen, Hao Long, Xiao-Dong Su, Xu Zhang, Jian-Hua Fu, Peng Lin, Lan-Jun Zhang, Tie-Hua Rong, Jia-Di Wu, Zhi-Chao Li, Hui-Lin Su, Ji-Yang Chen, Yun-Peng Yang, Yong-Bin Lin, Mian Xi, Hong Yang
30. [Comment] Stereotactic body radiotherapy plus neoadjuvant chemoimmunotherapy in operable non-small-cell lung cancer Rafał Dziadziuszko, Bartłomiej Tomasik
31. [Articles] Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study Yongfeng Yu, Qisen Guo, Yongchang Zhang, Jian Fang, Diansheng Zhong, Baogang Liu, Pinhua Pan, Dongqing Lv, Lin Wu, Yanqiu Zhao, Juan Li, Zhihua Liu, Chunling Liu, Haichuan Su, Yun Fan, Tongmei Zhang, Anwen Liu, Bo Jin, Ye Wang, Jianying Zhou, Zhihong Zhang, Fengming Ran, Xia Song, Michael Shi, Weiguo Su, Shun Lu, study group
32. [Comment] Savolitinib in NSCLC: progress in the MET exon 14 journey Tetsuya Mitsudomi
33. [Position Paper] An international consensus on the use of asthma biologics in pregnancy Jennifer Naftel, David J Jackson, Matthew Coleman, Grainne d'Ancona, Liam G Heaney, Paddy Dennison, Apostolos Bossios, Hitasha Rupani
34. [Comment] Navigating uncertainty: asthma biologics during pregnancy Imran Howell, Aleksandra Howell, Ian Pavord
35. [Comment] Expanding the indication of CFTR modulator combinations for people with cystic fibrosis with non-F508del variants Pierre-Régis Burgel
36. [Articles] Evaluation of elexacaftor–tezacaftor–ivacaftor treatment in individuals with cystic fibrosis and CFTRN1303K in the USA: a prospective, multicentre, open-label, single-arm trial George M Solomon, Rachel W Linnemann, Rachel Rich, Ashleigh Streby, Brian Buehler, Eric Hunter, Kadambari Vijaykumar, William R Hunt, John J Brewington, Andras Rab, Shasha P Bai, Adrianna L Westbrook, Carmel McNicholas-Bevensee, Jong Hong, Candela Manfredi, Cristina Barilla, Shingo Suzuki, Brian R Davis, Eric J Sorscher
37. [Review] Biological and therapeutic implications of the cancer-related germline mutation landscape in lung cancer Emmanouil Panagiotou, Ioannis A Vathiotis, Periklis Makrythanasis, Fred Hirsch, Triparna Sen, Konstantinos Syrigos
更新于 23 分钟前

近期历史最近 100 条记录

2024-11-26 [Spotlight] Lifetime non-smoker survives stage IV lung cancer four times Tony Kirby
2024-11-26 [Comment] 5 years of COVID-19: equity must lead the next pandemic response in a fractured multipolar world David S C Hui, Dorothy Yeboah-Manu, Jean B Nachega, Alfonso J Rodriguez-Morales, Tieble Traore, Markus Maeurer, Guiseppe Ippolito, Adam Zumla, Rizwan Ahmed, Osman Dar, Adeeba Kamarulzaman, Alimuddin Zumla
2024-11-23 [Articles] Development of an asthma health-care burden score as a measure of severity and predictor of remission in SARP III and U-BIOPRED: results from two major longitudinal asthma cohorts Joe G Zein, Nazanin Zounemat-Kerman, Ian M Adcock, Bo Hu, Amy Attaway, Mario Castro, Sven-Erik Dahlén, Loren C Denlinger, Serpil C Erzurum, John V Fahy, Benjamin Gaston, Annette T Hastie, Elliot Israel, Nizar N Jarjour, Bruce D Levy, David T Mauger, Wendy
2024-11-23 [Comment] A composite burden score for severe asthma Jean Bousquet, Renaud Louis, Bernardo Sousa-Pinto
2024-11-23 [Corrections] Correction to Lancet Respir Med 2024; published online Oct 29. https://doi.org/10.1016/S2213-2600(24)00264-9
2024-11-22 [Articles] Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial Dongsheng Yue, Wenxiang Wang, Hongxu Liu, Qixun Chen, Chun Chen, Lunxu Liu, Peng Zhang, Guofang Zhao, Fan Yang, Guang Han, Ying Cheng, Bentong Yu, Yue Yang, Haiquan Chen, Jie Jiang, Lijie Tan, Shidong Xu, Naiquan Mao, Jian Hu, Lanjun Zhang, Bin Yao, Sheng
2024-11-22 [Comment] New territories: perioperative chemoimmunotherapy in early-stage NSCLC Yusuke Okuma
2024-11-21 [Editorial] One health, one flu: the re-emergence of avian influenza The Lancet Respiratory Medicine
2024-11-16 [News] Health care in Ukraine: If everybody leaves, who will stay? Talha Burki
2024-11-14 [Articles] Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis Amy Shackleford, Liam G Heaney, Charlene Redmond, P Jane McDowell, John Busby
2024-11-14 [Comment] Asthma remission: a call for a globally standardised definition Marek Lommatzsch, J Christian Virchow
2024-11-14 [Spotlight] Thoracentesis: an old story and some new sources Emmanuel Drouin, Eric Wiel, Edouard Lansiaux, Jacalyn Duffin, Arnaud Chambellan
2024-11-12 [Comment] Managing tuberculosis before the onset of symptoms Dennis Falzon, Cecily Miller, Irwin Law, Katherine Floyd, Nimalan Arinaminpathy, Matteo Zignol, Tereza Kasaeva
2024-10-31 [Correspondence] Health promotion in the management of respiratory diseases: an Indian perspective Arundhati Garud, Debabani Biswas, Saibal Moitra, Subhabrata Moitra
2024-10-30 [Articles] Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08–2015 ENERGY): a randomised, open-label, pha Hervé Léna, Laurent Greillier, Claire Cropet, Olivier Bylicki, Isabelle Monnet, Clarisse Audigier-Valette, Lionel Falchero, Alain Vergnenègre, Pierre Demontrond, Margaux Geier, Florian Guisier, Stéphane Hominal, Chrystèle Locher, Romain Corre, Christos Ch
2024-10-30 [Comment] First-line treatment for advanced NSCLC in older patients and those with poor performance status Ziming Li, Shun Lu
2024-10-26 [Articles] Nintedanib for patients with lymphangioleiomyomatosis: a phase 2, open-label, single-arm study Sergio Harari, Davide Elia, Antonella Caminati, Jens Geginat, Francesca Luisi, Giuseppe Pelosi, Claudia Specchia, Olga Torre, Roberta Trevisan, Chiara Vasco, Maurizio Zompatori, Roberto Cassandro
2024-10-26 [Comment] The challenge of therapeutic options for patients with lymphangioleiomyomatosis Maria Molina-Molina
2024-10-24 [News] Youth vaping rates drop in US, but experts remain concerned Bryant Furlow
2024-10-23 [News] UK COVID-19 booster vaccination programme Priya Venkatesan
2024-10-19 [Articles] Global, regional, and national burden of pulmonary arterial hypertension, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 GBD 2021 Pulmonary Arterial Hypertension Collaborators
2024-10-19 [Comment] The global burden of pulmonary arterial hypertension: profound but improving? Joseph Newman, Joanna Pepke-Zaba
2024-10-19 [Corrections] Correction to Lancet Respir Med 2024; 12: 799–809
2024-10-18 [News] Mixed news on air pollution and child lung health Udani Samarasekera
2024-10-16 [Comment] Breaking barriers: holistic assessment of ability to work in patients with sarcoidosis Marjolein Drent, Anne-Marie Russell, Lesley Ann Saketkoo, Paolo Spagnolo, Marcel Veltkamp, Athol U Wells, representatives of the sarcoidosis community
2024-10-12 [Viewpoint] Empirical antibiotic therapy for sepsis: save the anaerobic microbiota Robert F J Kullberg, Bastiaan W Haak, Rishi Chanderraj, Hallie C Prescott, Robert P Dickson, W Joost Wiersinga
2024-10-12 [Editorial] Antimicrobial resistance: a global health emergency The Lancet Respiratory Medicine
2024-10-11 [Spotlight] Survival of sepsis masked by medications that hid diverticulitis Tony Kirby
2024-10-10 [Correspondence] Airway inflammation enhances the effectiveness of elexacaftor–tezacaftor–ivacaftor therapy for cystic fibrosis and CFTRN1303K mutation Martina Gentzsch, Charles R Esther, Carla M P Ribeiro
2024-10-09 [News] Phillip Morris sell Vectura after academic freeze-out Talha Burki
2024-10-04 [News] European Respiratory Society International Congress 2024 Priya Venkatesan
2024-10-02 [Articles] Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial Ruth L Goodall, Andrew J Nunn, Sarah K Meredith, Adamu Bayissa, Anuj K Bhatnagar, Chen-Yuan Chiang, Francesca Conradie, Narendran Gopalan, Meera Gurumurthy, Bruce Kirenga, Nana Kiria, Daniel Meressa, Ronelle Moodliar, Nosipho Ngubane, Mohammed Rassool, Ka
2024-10-02 [Comment] Towards shorter, safer, flexible, and more effective treatment regimens for drug-resistant tuberculosis Keertan Dheda, Christoph Lange
2024-09-27 [Comment] Strengthening intensive care: addressing challenges and embracing opportunities Elie Azoulay, Maurizio Cecconi, Jan J De Waele
2024-09-24 [Comment] Reflections 5 years on from the approval of ETI therapy Peter G Middleton, Jennifer L Taylor-Cousar
2024-09-20 [Comment] Serotonin pathway blockade in pulmonary arterial hypertension Marcin Kurzyna
2024-09-20 [Articles] Safety and efficacy of rodatristat ethyl for the treatment of pulmonary arterial hypertension (ELEVATE-2): a dose-ranging, randomised, multicentre, phase 2b trial Olivier Sitbon, Andris Skride, Jeremy Feldman, Sandeep Sahay, Oksana A Shlobin, Vallerie McLaughlin, Hossein-Ardeschir Ghofrani, David Langleben, Ed Parsley, Gwyn D'Souza, Tonya Marmon, Watiri Kamau-Kelley, Renee Jones, Ravi Grewal, Steve Wring, Michelle
2024-09-19 [Articles] Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial Ze-Rui Zhao, Shi-Liang Liu, Ting Zhou, Gang Chen, Hao Long, Xiao-Dong Su, Xu Zhang, Jian-Hua Fu, Peng Lin, Lan-Jun Zhang, Tie-Hua Rong, Jia-Di Wu, Zhi-Chao Li, Hui-Lin Su, Ji-Yang Chen, Yun-Peng Yang, Yong-Bin Lin, Mian Xi, Hong Yang
2024-09-19 [Comment] Stereotactic body radiotherapy plus neoadjuvant chemoimmunotherapy in operable non-small-cell lung cancer Rafał Dziadziuszko, Bartłomiej Tomasik
2024-09-17 [Editorial] Extreme heat: holistic thinking in respiratory medicine The Lancet Respiratory Medicine
2024-09-13 [Correspondence] Top ten research priorities for sepsis research: UK James Lind Alliance priority setting partnership Joanne McPeake, Mark Oakes, Colin Graham, Nahid Ahmad, Nazir Lone, Bronwen Connolly, James Lind Alliance Sepsis PSP Steering Group
2024-09-11 [Articles] Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory st Yongfeng Yu, Qisen Guo, Yongchang Zhang, Jian Fang, Diansheng Zhong, Baogang Liu, Pinhua Pan, Dongqing Lv, Lin Wu, Yanqiu Zhao, Juan Li, Zhihua Liu, Chunling Liu, Haichuan Su, Yun Fan, Tongmei Zhang, Anwen Liu, Bo Jin, Ye Wang, Jianying Zhou, Zhihong Zhan
2024-09-11 [Comment] Savolitinib in NSCLC: progress in the MET exon 14 journey Tetsuya Mitsudomi
2024-09-10 [Articles] Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months Charles S Haworth, Michal Shteinberg, Kevin Winthrop, Alan Barker, Francesco Blasi, Katerina Dimakou, Lucy C Morgan, Anne E O'Donnell, Felix C Ringshausen, Oriol Sibila, Rachel M Thomson, Kevin J Carroll, Federica Pontenani, Paola Castellani, James D Chal
2024-09-10 [Comment] PROMISing results for inhaled antibiotics in bronchiectasis Marta María García Clemente, Guillermo Suárez Cuartín
2024-09-10 [Articles] Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled tr Baohui Han, Trevor Feinstein, Yuankai Shi, Gongyan Chen, Yu Yao, Chunhong Hu, Jianhua Shi, Jifeng Feng, Huijuan Wu, Ying Cheng, Qi-sen Guo, Zhijun Jie, Feng Ye, Yiping Zhang, Zhihua Liu, Weidong Mao, Liangming Zhang, Junguo Lu, Jun Zhao, Lyudmila Bazhenov
2024-09-10 [Comment] Plinabulin, a microtubule destabilising agent, in non-small-cell lung cancer: lessons from the DUBLIN-3 trial Rafael Rosell, María González-Cao, Miguel Angel Molina-Vila
2024-09-09 [Articles] Mirtazapine to alleviate severe breathlessness in patients with COPD or interstitial lung diseases (BETTER-B): an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trial Irene J Higginson, Sarah T Brown, Adejoke O Oluyase, Peter May, Matthew Maddocks, Massimo Costantini, Sabrina Bajwah, Charles Normand, Claudia Bausewein, Steffen T Simon, Karen Ryan, David C Currow, Miriam J Johnson, Simon P Hart, Hannah Mather, Malgorzat
2024-09-09 [Comment] The ongoing battle against breathlessness Kris Mooren, Huib A M Kerstjens
2024-09-09 [Comment] Choice overload for RSV prevention—how to form your opinion Natasha Halasa, Louis Bont
2024-09-09 [Spotlight] Louis Bont – leading efforts to find an RSV vaccine Tony Kirby
2024-09-09 [Series] Early-life respiratory syncytial virus disease and long-term respiratory health Heather J Zar, Ferdinand Cacho, Tahira Kootbodien, Asuncion Mejias, Justin R Ortiz, Renato T Stein, Tina V Hartert
2024-09-09 [Series] Respiratory syncytial virus infections in adults: a narrative review Joanne G Wildenbeest, David M Lowe, Joseph F Standing, Christopher C Butler
2024-09-05 [Comment] ECMO: more than just a bridge over troubled waters? Ryan Ruiyang Ling, Kollengode Ramanathan, Kiran Shekar
2024-09-05 [Comment] Continuing ECMO with no possible transition to recovery or transplant Alexander Supady, William L Allen, Thaddeus M Pope
2024-08-31 [Articles] Efficacy and safety of gefapixant in women with chronic cough and cough-induced stress urinary incontinence: a phase 3b, randomised, multicentre, double-blind, placebo-controlled trial Surinder S Birring, Linda Cardozo, Roger Dmochowski, Peter Dicpinigaitis, Amna Afzal, Carmen La Rosa, Susan Lu, Allison Martin Nguyen, Ruji Yao, Paul A Reyfman
2024-08-31 [Comment] Easing the stress of chronic cough Marta Dąbrowska, Lorcan McGarvey
2024-08-29 [Position Paper] An international consensus on the use of asthma biologics in pregnancy Jennifer Naftel, David J Jackson, Matthew Coleman, Grainne d'Ancona, Liam G Heaney, Paddy Dennison, Apostolos Bossios, Hitasha Rupani
2024-08-29 [Comment] Navigating uncertainty: asthma biologics during pregnancy Imran Howell, Aleksandra Howell, Ian Pavord
2024-08-27 [Comment] Expanding the indication of CFTR modulator combinations for people with cystic fibrosis with non-F508del variants Pierre-Régis Burgel
2024-08-27 [Articles] Evaluation of elexacaftor–tezacaftor–ivacaftor treatment in individuals with cystic fibrosis and CFTRN1303K in the USA: a prospective, multicentre, open-label, single-arm trial George M Solomon, Rachel W Linnemann, Rachel Rich, Ashleigh Streby, Brian Buehler, Eric Hunter, Kadambari Vijaykumar, William R Hunt, John J Brewington, Andras Rab, Shasha P Bai, Adrianna L Westbrook, Carmel McNicholas-Bevensee, Jong Hong, Candela Manfred
2024-08-22 [News] The UK COVID-19 Inquiry and critical care Priya Venkatesan
2024-08-22 [Spotlight] One lung but many laughs at the Edinburgh Festival Fringe Peter Ranscombe
2024-08-22 [Spotlight] Saving lives with oxygen and monocytes at Edinburgh Fringe Peter Ranscombe
2024-08-21 [Comment] New thinking and a new direction in bronchiectasis Ian D Pavord
2024-08-17 [Articles] Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab–ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, rando Yoshimasa Shiraishi, Shogo Nomura, Shunichi Sugawara, Hidehito Horinouchi, Yasuto Yoneshima, Hidetoshi Hayashi, Koichi Azuma, Satoshi Hara, Seiji Niho, Ryo Morita, Masafumi Yamaguchi, Toshihide Yokoyama, Kiyotaka Yoh, Takayasu Kurata, Hiroaki Okamoto, Mas
2024-08-17 [Spotlight] Fatal dyspnoea at the Palace of Versailles Emmanuel Drouin, Serge Wasersztrum, Arnaud Chambellan
2024-08-17 [Comment] Anti-CTLA-4 in non-small-cell lung cancer: insights from the NIPPON study Molly S C Li, Stephanie P L Saw, Alfredo Addeo
2024-08-15 [Editorial] FLiRTing with danger as SARS-CoV-2 variants evolve The Lancet Respiratory Medicine
2024-08-14 [Comment] Compassionate use trials and equitable access to variant-specific treatment for cystic fibrosis Katherine Odem-Davis, Jennifer L Taylor-Cousar
2024-08-14 [Articles] The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study Pierre-Régis Burgel, Isabelle Sermet-Gaudelus, Emmanuelle Girodon, Isabelle Durieu, Véronique Houdouin, Camille Audousset, Julie Macey, Dominique Grenet, Michele Porzio, Marlène Murris-Espin, Philippe Reix, Mélisande Baravalle, Chantal Belleguic, Laurent
2024-08-13 [Articles] High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial Jiayi Yu, Leilei Jiang, Lina Zhao, Xue Yang, Xiaomin Wang, Dan Yang, Minglei Zhuo, Hanxiao Chen, Wei Huang, Zhengfei Zhu, Min Zhang, Yipeng Song, Quanfu Li, Zhanshu Ma, Qifeng Wang, Yanli Qu, Rong Yu, Huiming Yu, Jun Zhao, Anhui Shi, Trial Management Grou
2024-08-13 [Comment] New strategies for patients with limited-stage small-cell lung cancer Famke L Schneiders, Suresh Senan
2024-08-09 [Comment] Patient-reported outcomes: missing in asthma remission Amy Hai Yan Chan, Paul Leong, John Politis, Vanessa M McDonald, Philip Bardin
2024-08-08 [Articles] Estimated number of lives directly saved by COVID-19 vaccination programmes in the WHO European Region from December, 2020, to March, 2023: a retrospective surveillance study Margaux M I Meslé, Jeremy Brown, Piers Mook, Mark A Katz, José Hagan, Roberta Pastore, Bernhard Benka, Monika Redlberger-Fritz, Nathalie Bossuyt, Veerle Stouten, Catharina Vernemmen, Elisabet Constantinou, Marek Maly, Jan Kynčl, Ondrej Sanca, Tyra Grove K
2024-08-08 [Comment] Impact of COVID-19 vaccination programmes in Europe: lives saved and lessons learned Oliver J Watson, Alexandra B Hogan
2024-08-02 [News] US FDA approves menthol e-cigarette products Bryant Furlow
2024-07-24 [Comment] Foritinib, a type II ROS1 inhibitor for NSCLC Jii Bum Lee, Sai-Hong Ignatius Ou
2024-07-24 [Articles] Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study Jin-Ji Yang, Jianying Zhou, Si-Yang Maggie Liu, Mingjun Li, Zhiye Zhang, Ying Cheng, Yun Fan, Hongming Pan, Baoqing Wang, Gongyan Chen, Ke Wang, Liyan Jiang, Yanping Hu, Jianhua Shi, Xiaorong Dong, Cuimin Ding, Yunpeng Liu, Zhe Liu, Wangjun Liao, Wei Li,
2024-07-20 [Correspondence] Sedation targets in the ICU: thinking beyond protocols Bruna Brandao Barreto, Mariana Luz, Dimitri Gusmao-Flores
2024-07-17 [News] US Supreme Court overturns Chevron doctrine Bryant Furlow
2024-07-16 [Articles] Cluster analysis of blood biomarkers to identify molecular patterns in pulmonary fibrosis: assessment of a multicentre, prospective, observational cohort with independent validation Hernan P Fainberg, Yuben Moodley, Isaac Triguero, Tamera J Corte, Jannie M B Sand, Diana J Leeming, Morten A Karsdal, Athol U Wells, Elisabetta Renzoni, John Mackintosh, Dino B A Tan, Roger Li, Joanne Porte, Rebecca Braybrooke, Gauri Saini, Simon R Johnso
2024-07-16 [Review] Influenza-associated and COVID-19-associated pulmonary aspergillosis in critically ill patients Simon Feys, Agostinho Carvalho, Cornelius J Clancy, Jean-Pierre Gangneux, Martin Hoenigl, Katrien Lagrou, Bart J A Rijnders, Laura Seldeslachts, Lore Vanderbeke, Frank L van de Veerdonk, Paul E Verweij, Joost Wauters
2024-07-16 [Comment] Biomarker-defined endotypes of pulmonary fibrosis A Scott McCall, Jonathan A Kropski
2024-07-13 [Spotlight] Alin Gragossian: from emergency medicine resident to heart transplant recipient Tony Kirby
2024-07-12 [Articles] Nasal sprays and behavioural interventions compared with usual care for acute respiratory illness in primary care: a randomised, controlled, open-label, parallel-group trial Paul Little, Jane Vennik, Kate Rumsby, Beth Stuart, Taeko Becque, Michael Moore, Nick Francis, Alastair D Hay, Theo Verheij, Katherine Bradbury, Kate Greenwell, Laura Dennison, Sian Holt, James Denison-Day, Ben Ainsworth, James Raftery, Tammy Thomas, Chri
2024-07-12 [Comment] Treating acute respiratory illness: the need to be proactive Evangelos J Giamarellos-Bourboulis
2024-07-10 [Spotlight] Fasting in Ramadan and respiratory diseases Talha Burki
2024-07-09 [Health-care Development] Interactions between respiratory syncytial virus and Streptococcus pneumoniae in the pathogenesis of childhood respiratory infections: a systematic review Sjanna B Besteman, Debby Bogaert, Louis Bont, Asuncion Mejias, Octavio Ramilo, Daniel M Weinberger, Ron Dagan
2024-07-09 [Spotlight] James Chalmers: A maverick making an impact in bronchiectasis Peter Ranscombe
2024-07-04 [Review] Rethinking bronchiectasis as an inflammatory disease Merete B Long, Sanjay H Chotirmall, Michal Shteinberg, James D Chalmers
2024-06-21 [News] Whooping cough cases rising Priya Venkatesan
2024-06-15 [Review] Biological and therapeutic implications of the cancer-related germline mutation landscape in lung cancer Emmanouil Panagiotou, Ioannis A Vathiotis, Periklis Makrythanasis, Fred Hirsch, Triparna Sen, Konstantinos Syrigos
2024-06-15 [Correspondence] Potential for personalised and biomarker-guided COPD self-treatment approaches Anke Lenferink, Emanuel Citgez, Paul D L P M van der Valk, Job van der Palen, Tanja W Effing, Marjolein G J Brusse-Keizer
2024-06-14 [Comment] Moving forward in IPF: lessons learned from clinical trials Ganesh Raghu, Thomas R Fleming
2024-06-13 [Correspondence] Challenges of modulating the risk of bronchopulmonary dysplasia in clinical trials Brady Thomas, Patrick McNamara, Jennifer Bermick
2024-06-13 [Correspondence] Challenges of modulating the risk of bronchopulmonary dysplasia in clinical trials – Authors' reply John Lowe, Janet Berrington, David Gillespie, Mark Turner, Sailesh Kotecha
2024-06-12 [Articles] Hypothermia for expanded criteria organ donors in kidney transplantation in France (HYPOREME): a multicentre, randomised controlled trial The HYPOREME Trial Group
2024-06-12 [Comment] Mild hypothermia for expanded criteria kidney donors: balancing evidence and uncertainty Riccardo Campi, Vincenzo Li Marzi, Sergio Serni
2024-06-12 [News] 2024 American Thoracic Society International Conference Priya Venkatesan

匿名用户只展示最新 100 条榜单历史,更多历史数据请登录后查看,支持时光机按天筛选